Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals stock rose 4.0% in morning trading today, hitting a new 52-week high of $972.06, as a wave of analyst price target increases following the company’s exceptional third-quarter 2026 results continued to propel shares higher. The company reported adjusted earnings of $20.07 per share, up 70% year-over-year and well above the analyst consensus of approximately $16.19, while revenue surged 36% to $5.116 billion, topping Wall Street’s estimate of roughly $4.54 billion. CEO Leonard S. Schleifer called it "an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales."

Multiple firms raised their price targets in response: BofA Securities lifted its target from $908 to $1,030 with a Buy rating, Baird moved from $761 to $875 with a Neutral, Cantor Fitzgerald raised its target from $795 to $980 maintaining an Overweight, and Canaccord Genuity boosted its target from $922 to $1,175 with a Buy. Guggenheim also raised its price objective from $1,030 to $1,100, maintaining a Buy rating. Additional support came from updated Phase 3 trial data showing Libtayo reduced the risk of death by 37% in cutaneous squamous cell carcinoma.

Stocks were climbing in early trading as oil prices tumbled and technology shares rebounded after markets tumbled the prior Friday when tech stocks slid amid disappointing earnings from companies including Amazon and Alphabet, with the Nasdaq posting its worst single-day performance since June. Market attention today is centered on mixed sector performance, upcoming labor data, manufacturing activity, Treasury yields, and continued concentration in technology and AI stocks.

The combination of record quarterly results, a landmark Sanofi alliance expansion worth up to $8 billion, and a broad-based upgrade cycle from Wall Street analysts created a powerful, multi-day momentum trade for Regeneron. Regeneron’s shares are not very volatile and have only had a handful of moves greater than 5% over the last year, underscoring just how significantly this earnings catalyst has shifted the market’s perception of the business.